ClinicalTrials.gg
CompletedNCT05463068Updated Apr 17, 2026Results posted

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

A Phase 3 interventional study of NVX-Cov2373 in COVID-19 and SARS-CoV-2 Infection, sponsored by Novavax. Completed at 30 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Novavax · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
911
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 — none open to participants now, 2 under way, none of them phase 3. NVX-CoV2373 adjuvated lipid nanoparticle · COVID-19.

Enrollment
11th of 18
911 · median 997
Started
2022
with 4 others
Phase 3
7 of 18
none open now
Registered
9th of 18
by date
Lead sponsor
12 of 18
Novavax

Among the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19, this one is the 11th largest by enrollment, is one of 5 that started in 2022, is one of 7 in phase 3, and was the 9th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 is open now. The open studies under COVID-19, anywhere →

About NVX-CoV2373 adjuvated lipid nanoparticle

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 as a file.
02

Study summary

This is a randomized, Phase 3 study comparing the immunogenicity and safety of 3 different lots of Novavax vaccine with Matrix-M™ adjuvant (NVX-CoV2373).The study will enroll approximately 900 previously vaccinated adults 18 to 49 years of age, inclusive.

Read the detailed description

This is a randomized, Phase 3 study comparing the immunogenicity and safety of 3 different lots of Novavax vaccine with Matrix-M™ adjuvant (NVX-CoV2373). The study will enroll approximately 900 previously vaccinated adults 18 to 49 years of age, inclusive. Participants will be screened at baseline with the goal of enrolling approximately 900 previously vaccinated participants. Participants will be randomized 1:1:1 to receive 1 dose of the vaccine from 1 of 3 different lots, given on Day 1, at a dose level of 5 µg of antigen with 50 µg of Matrix-M adjuvant. All participants will remain on study for immunogenicity and safety data collection through 28 days following the vaccination.

03

Conditions studied

  • COVID-19
  • SARS-CoV-2 Infection

Keywords

  • Coronavirus
  • COVID-19
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be included in this study, each individual must satisfy all of the following criteria:

  1. Adults 18 to 49 years of age, inclusive, at screening
  2. Willing and able to give prior to study enrollment and to comply with study procedures.
  3. Participants of (defined as any participant who has experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or [defined as amenorrhea at least 12 consecutive months]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through the end of study (EOS) visit OR agree to consistently use a medically acceptable method of from at least 28 days prior to enrollment and through the EOS visit.
  4. Is medically stable, as determined by the investigator (based on review of health status, vital signs [to include body temperature], medical history, and targeted physical examination [to include body weight]). Vital signs must be within medically acceptable ranges prior to the study vaccination
  5. Agree to not participate in any other SARS-CoV-2 prevention or treatment trials for the duration of the study.

    Note: For participants who become hospitalized with coronavirus disease 2019 (COVID-19), participation in treatment studies is permitted.

  6. Documented receipt of either 2 or 3 doses of the investigational Novavax vaccine with Matrix-M adjuvant (NVX- CoV2373); OR documented receipt of a full course of an FDA-authorized/approved COVID-19 vaccine; OR documented receipt of a full course of heterologous COVID-19 vaccines mentioned above. The most recent dose must have been administered at least 6 months prior to study vaccination.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded from the study.

  1. History of laboratory-confirmed (by polymerase chain reaction [PCR] or rapid antigen test)COVID-19 infection ≤ 4 months prior to randomization.
  2. Current participation in research involving receipt of an product (drug/biologic/device).
  3. Any known allergies or history of anaphylaxis to the active substance or any of the other ingredients contained in the investigational product.
  4. Any or immunodeficiency disease/condition (iatrogenic or congenital) or therapy that causes .
  5. Received any vaccine ≤ 90 days prior to study vaccination, except for influenza vaccine which may be received 4 days prior to study vaccine, or rabies vaccine which may be received at any time if medically indicated.
  6. Received immunoglobulin, blood-derived products, or immunosuppressant drugs within 90 days prior to study vaccination, except for rabies immunoglobulin which may be given if medically indicated.
  7. Active cancer () on chemotherapy that is judged to cause significant immunocompromise within 1 year prior to first study vaccination (with the exception of malignancy cured via excision, at the discretion of the investigator).
  8. Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to the EOS visit.
  9. Suspected or known history of alcohol abuse or drug addiction within 3 months prior to the study vaccine dose that, in the opinion of the investigator, might interfere with protocol compliance.
  10. Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the trial vaccine or interpretation of study results (including neurologic or psychiatric conditions likely to impair the quality of safety reporting).
  11. Study team member or immediate family member of any study team member (inclusive of Sponsor, clinical research organization [CRO], and study site personnel involved in the conduct or planning of the study).
  12. Participants with a history of myocarditis or pericarditis.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
911 participants (actual)

Study arms

  • Experimental
    Lot 1

    1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 1.

    Drug: NVX-Cov2373

  • Experimental
    Lot 2

    1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 1.

    Drug: NVX-Cov2373

  • Experimental
    Lot 3

    1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 1.

    Drug: NVX-Cov2373

Interventions

  • Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1

    Also known as: SARS-CoV-2 rS/Matrix-M Adjuvant

06

What researchers measure

Primary outcomes

  1. Serum Immunoglobulin G (IgG) Antibody Levels to the SARS-CoV-2 Spike Protein Expressed as Geometric Mean ELISA Unit [GMEUs]

    Serum Immunoglobulin G (IgG) geometric mean ELISA unit concentrations (GMEU/mL) to the SARS-CoV-2 spike protein at Day 29 in each treatment arm.

    Time frame: Baseline (Day 1) and Day 29

Secondary outcomes

  1. Serum IgG Antibody Levels to the SARS-CoV-2 Spike Protein Expressed as Seroconversion Rate (SCR)

    Proportion of participants in each treatment arm who achieve seroconversion (≥ 4-fold increase from baseline) in IgG concentrations to the SARS-CoV-2 spike protein at Day 29.

    Time frame: Day 29

  2. Neutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) Expressed as Geometric Mean Titer [GMT]

    Neutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) of 3 Lots of NVX-CoV2373 at Day 1 and Day 29

    Time frame: Baseline (Day 1) to Day 29

  3. Neutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) Expressed as SCR

    Neutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) of 3 Lots of NVX-CoV2373 at Day 29

    Time frame: Day 29

  4. hACE2 Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) Expressed as GMT

    hACE2 Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) the 3 Lots of NVX-CoV2373 at Day 1 to Day 29

    Time frame: Baseline (Day 1) to Day 29

  5. Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) Expressed as SCR

    Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) the 3 Lots of NVX-CoV2373 at Day 29

    Time frame: Day 29

  6. Number of Participants With Medically Attended Adverse Event(s) (MAAEs), Adverse Event(s) of Special Interest (AESIs), and Serious Adverse Event(s) (SAEs)

    Number of participants Medically Attended Adverse Event(s) (MAAEs), Adverse event(s) of Special Interest (AESIs), and Serious Adverse Event(s) (SAEs)

    Time frame: Day 1 to Day 29

  7. Incidence and Severity of MAAEs Through Day 29

    Incidence, duration, severity, and relationship of MAAEs through Day 29 (ie, 28 days after vaccine dose)

    Time frame: Day 29

  8. Number of Participants With Unsolicited Treatment-Emergent Adverse Events by COVID-19

    Number of Participants with Unsolicited Treatment-Emergent Adverse Events by COVID-19 throughout the study at Day 29

    Time frame: Day 29

07

Results

Posted Apr 17, 2026

Participant flow

Participant flow — Overall Study
MilestoneLot 1Lot 2Lot 3
Started298303304
Completed283289293
Not completed151411
Withdrew: Lost to follow-up425
Withdrew: Withdrawal by subject422
Withdrew: Sponsor decision693
Withdrew: Others111

Outcome measures

PrimarySerum Immunoglobulin G (IgG) Antibody Levels to the SARS-CoV-2 Spike Protein Expressed as Geometric Mean ELISA Unit [GMEUs]

Serum Immunoglobulin G (IgG) geometric mean ELISA unit concentrations (GMEU/mL) to the SARS-CoV-2 spike protein at Day 29 in each treatment arm.

Time frame:
Baseline (Day 1) and Day 29
Reported as:
Geometric mean · Elisa Units per mL
Serum Immunoglobulin G (IgG) Antibody Levels to the SARS-CoV-2 Spike Protein Expressed as Geometric Mean ELISA Unit [GMEUs]
Elisa Units per mLLot 1Lot 2Lot 3
Baseline (Day 1)34294.3 (29549.6 to 39800.9)36142.6 (31430.8 to 41560.8)33233.4 (28863.0 to 38265.4)
Day 2991945.8 (82821.7 to 102075.0)93084.2 (84250.8 to 102843.7)88811.3 (86164.5 to 96589.6)
SecondarySerum IgG Antibody Levels to the SARS-CoV-2 Spike Protein Expressed as Seroconversion Rate (SCR)

Proportion of participants in each treatment arm who achieve seroconversion (≥ 4-fold increase from baseline) in IgG concentrations to the SARS-CoV-2 spike protein at Day 29.

Time frame:
Day 29
Reported as:
Number · Percentage of participants
Serum IgG Antibody Levels to the SARS-CoV-2 Spike Protein Expressed as Seroconversion Rate (SCR)
Percentage of participantsLot 1Lot 2Lot 3
Serum IgG Antibody Levels to the SARS-CoV-2 Spike Protein Expressed as Seroconversion Rate (SCR)23.0 (18.2 to 28.5)21.2 (16.5 to 26.5)25.4 (20.4 to 30.8)
SecondaryNeutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) Expressed as Geometric Mean Titer [GMT]

Neutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) of 3 Lots of NVX-CoV2373 at Day 1 and Day 29

Time frame:
Baseline (Day 1) to Day 29
Reported as:
Geometric mean · geometric mean titers
Neutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) Expressed as Geometric Mean Titer [GMT]
geometric mean titersLot 1Lot 2Lot 3
Baseline (Day 1)1211.0 (1028.9 to 1425.2)1289.4 (1114.2 to 1492.3)1103.7 (950.1 to 1282.1)
Day 292838.7 (2532.6 to 3181.8)2823.5 (2529.0 to 3152.4)2603.2 (2341.2 to 2894.6)
SecondaryNeutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) Expressed as SCR

Neutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) of 3 Lots of NVX-CoV2373 at Day 29

Time frame:
Day 29
Reported as:
Number · Percentage of participants
Neutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) Expressed as SCR
Percentage of participantsLot 1Lot 2Lot 3
Neutralizing Antibody Titers for SARS-CoV-2 Wild-Type Virus (Wuhan) Expressed as SCR32.4 (26.9 to 38.2)32.9 (27.4 to 38.7)35.9 (30.3 to 41.7)
SecondaryhACE2 Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) Expressed as GMT

hACE2 Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) the 3 Lots of NVX-CoV2373 at Day 1 to Day 29

Time frame:
Baseline (Day 1) to Day 29
Reported as:
Geometric mean · geometric mean titers
hACE2 Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) Expressed as GMT
geometric mean titersLot 1Lot 2Lot 3
Baseline (Day 1)142.3 (121.6 to 166.6)142.3 (127.0 to 170.5)128.8 (110.9 to 149.5)
Day 29332.1 (299.1 to 368.7)329.1 (296.9 to 364.8)319.1 (289.9 to 351.2)
SecondaryHuman Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) Expressed as SCR

Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) the 3 Lots of NVX-CoV2373 at Day 29

Time frame:
Day 29
Reported as:
Number · Percentage of participants
Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) Expressed as SCR
Percentage of participantsLot 1Lot 2Lot 3
Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Antibody Titers Specific for the SARS-CoV-2 Spike Protein (Wuhan) Expressed as SCR20.4 (15.8 to 25.8)18.6 (14.2 to 23.7)23.2 (18.5 to 28.6)
SecondaryNumber of Participants With Medically Attended Adverse Event(s) (MAAEs), Adverse Event(s) of Special Interest (AESIs), and Serious Adverse Event(s) (SAEs)

Number of participants Medically Attended Adverse Event(s) (MAAEs), Adverse event(s) of Special Interest (AESIs), and Serious Adverse Event(s) (SAEs)

Time frame:
Day 1 to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Medically Attended Adverse Event(s) (MAAEs), Adverse Event(s) of Special Interest (AESIs), and Serious Adverse Event(s) (SAEs)
ParticipantsLot 1Lot 2Lot 3
Serious AEs011
MAAEs151212
AESIs000
SecondaryIncidence and Severity of MAAEs Through Day 29

Incidence, duration, severity, and relationship of MAAEs through Day 29 (ie, 28 days after vaccine dose)

Time frame:
Day 29
Reported as:
Count of participants · Participants
Incidence and Severity of MAAEs Through Day 29
ParticipantsLot 1Lot 2Lot 3
MAAEs151212
Related MAAEs222
SecondaryNumber of Participants With Unsolicited Treatment-Emergent Adverse Events by COVID-19

Number of Participants with Unsolicited Treatment-Emergent Adverse Events by COVID-19 throughout the study at Day 29

Time frame:
Day 29
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Treatment-Emergent Adverse Events by COVID-19
ParticipantsLot 1Lot 2Lot 3
Unsolicited TEAEs151212
Related TEAEs222

Adverse events

Collected over 29 Days. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lot 10/298 (0%)0/298 (0%)7/298 (2.3%)
Lot 20/303 (0%)1/303 (0.3%)3/303 (1%)
Lot 30/304 (0%)1/304 (0.3%)4/304 (1.3%)
Most frequent serious events
Most frequent serious events
EventLot 1Lot 2Lot 3
Non-cardiac chest painGeneral disorders0/2981/3030/304
Escherichia infectionInfections and infestations0/2980/3031/304
Most frequent other events
Most frequent other events
EventLot 1Lot 2Lot 3
COVID-19Infections and infestations7/2983/3034/304

Baseline characteristics

Safety Analysis Set

Age, Continuous
Age, Continuous(years)Lot 1Lot 2Lot 3Total
Mean36.2 ± 8.3136.5 ± 8.8036.6 ± 8.0636.4 ± 8.39
Sex: Female, Male
Sex: Female, Male(Participants)Lot 1Lot 2Lot 3Total
Female175165186526
Male123138118379
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lot 1Lot 2Lot 3Total
Hispanic or Latino504152143
Not Hispanic or Latino245259248752
Unknown or Not Reported33410
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lot 1Lot 2Lot 3Total
American Indian or Alaska Native3137
Asian1110930
Black or African American546151166
Native Hawaiian or Other Pacific Islander0033
White or Caucasian219223228670
Other83920
Not reported/specified3519
Previous SARS-CoV-2 infection, n (%)
Previous SARS-CoV-2 infection, n (%)(Participants)Lot 1Lot 2Lot 3Total
Count of participants17131444
PCR, n (%)
PCR, n (%)(Participants)Lot 1Lot 2Lot 3Total
Positive78621
Negative282288289859
Missing97925
08

Study locations

30 sites
  • Long Beach Clinical Trial Services Inc.
    Long Beach, California 90806, United States
  • Benchmark Research
    Sacramento, California 95864, United States
  • Accel Clinical Research
    DeLand, Florida 32720, United States
  • Research Centers of America
    Hollywood, Florida 33024, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Multi-Specialty Research Associates, Inc.
    Lake City, Florida 32055, United States
  • Cen/Excel ACMR
    Atlanta, Georgia 30331, United States
  • Meridian Clinical Research
    Savannah, Georgia 31406, United States
  • CRA Headlands
    Stockbridge, Georgia 30281, United States
  • Velocity Clinical Research
    Boise, Idaho 83642, United States
  • Meridian Clinical Research
    Sioux City, Iowa 51106, United States
  • Meridian Clinical Research
    Baton Rouge, Louisiana 70809, United States
  • MedPharmics
    Gulfport, Mississippi 39503, United States
  • Sundance Clinical Research
    St Louis, Missouri 63141, United States
  • Meridian Clinical Research
    Norfolk, Nebraska 68701, United States
  • Meridian Clinical Research
    Omaha, Nebraska 68134, United States
  • Meridian Clinical Research
    Endwell, New York 13760, United States
  • Rochester Clinical Research
    Rochester, New York 14609, United States
  • OnSite Clinical Solutions, LLC
    Charlotte, North Carolina 28208, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Velocity Clinical Research
    Cleveland, Ohio 44122, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Tekton Research
    Yukon, Oklahoma 73099, United States
  • Velocity Clinical Research
    Grants Pass, Oregon 97527, United States
  • Velocity Clinical Research
    East Greenwich, Rhode Island 02818, United States
  • Benchmark Research
    Austin, Texas 78705, United States
  • Tekton Research
    Austin, Texas 78747, United States
  • Benchmark Research
    Houston, Texas 76135, United States
  • Research Your Health
    Plano, Texas 75093, United States
  • Tekton Research
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Raiser F, Davis M, Adelglass J, Cai MR, Chau G, Cloney-Clark S, Eickhoff M, Kalkeri R, McKnight I, Plested J, Zhu M, Dunkle LM; 2019nCoV-307 study team. Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults. Vaccine. 2023 Sep 22;41(41):5965-5973. doi: 10.1016/j.vaccine.2023.07.056. Epub 2023 Aug 30. PubMed 37652823 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Aug 2022, 1 month.

Results were first posted in Apr 2026, 3 years 8 months after primary completion. A results delay was requested in Mar 2023.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2022
First posted
Jul 18, 2022
StartActual
Jul 11, 2022
Primary completionActual
Aug 17, 2022
CompletionActual
Sep 1, 2022
Results delay requested
Mar 29, 2023
Results first posted
Apr 17, 2026
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05463068
Lead sponsor
Novavax
Responsible party
Sponsor
First posted
Jul 18, 2022
Start date
Jul 11, 2022
Primary completion
Aug 17, 2022
Completion
Sep 1, 2022
Results posted
Apr 17, 2026
Last update
Apr 17, 2026

Study contacts

Clinical Development
study director · Novavax, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle

Start the discussion